Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
LC–MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics 3 days 1 hours 2 mins 28 secs REGISTER NOW

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • eBook: Precision bioanalysis for every molecule
  • Global initiative seeks to fast-track personalized therapies for rare diseases
  • Editor’s highlights from NextGen Biomed 2026

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

23 SEP 2016 ANTIBODIES | ADCS
Best practice recommendations for the transfer of cell-based assays for the measurement of neutralizing anti-drug antibodies
1 AUG 2014 INTERVIEWS
Interview with Sufyan Maqbool (MedImmune) on capillary microsampling
4 FEB 2014 GENERAL INTEREST
Novel device can rapidly separate and identify Escherichia coli bacteria
18 JUN 2013 INTERVIEWS
Interview with Mike Oliver on sample preparation method optimization for increased efficiency in bioanalytical workflows
13 SEP 2012 DATA PROCESSING AND INTERPRETATION
Strategies to estimate and improve drug tolerance in anti-drug antibody assays
7 OCT 2014 GENERAL INTEREST
Stable isotope-labeling studies in metabolomics: new insights into structure and dynamics of metabolic networks
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility
  • Editorial Policies

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone